These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28818465)

  • 21. Is triple negative a prognostic factor in breast cancer?
    Nishimura R; Arima N
    Breast Cancer; 2008; 15(4):303-8. PubMed ID: 18369692
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.
    Bayoglu IV; Kucukzeybek BB; Kucukzeybek Y; Varol U; Yildiz I; Alacacioglu A; Akyol M; Demir L; Dirican A; Yildiz Y; Salman T; Tarhan MO
    Biomed Pharmacother; 2015 Mar; 70():190-5. PubMed ID: 25776500
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Talen-mediated girdin knockout downregulates cell proliferation, migration and invasion in human esophageal carcinoma ECA109 cells.
    Cao K; Jiang W; Cao P; Zou Q; Xiao S; Zhou J; Huang C
    Mol Med Rep; 2014 Aug; 10(2):848-54. PubMed ID: 24865549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
    Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
    Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis.
    Zhou B; Xu L; Ye J; Xin L; Duan X; Liu Y
    Anticancer Res; 2017 Aug; 37(8):4615-4621. PubMed ID: 28739761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.
    Schmidt G; Gerlinger C; Juhasz-Böss I; Stickeler E; Rody A; Liedtke C; Wimberger P; Link T; Müller E; Fehm T; Abel M; Stein S; Bohle R; Endrikat J; Solomayer EF
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1369-76. PubMed ID: 27008006
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
    Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
    Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Axillary lymph node micrometastases decrease triple-negative early breast cancer survival.
    Houvenaeghel G; Sabatier R; Reyal F; Classe JM; Giard S; Charitansky H; Rouzier R; Faure C; Garbay JR; Daraï E; Hudry D; Gimbergues P; Villet R; Lambaudie E
    Br J Cancer; 2016 Oct; 115(9):1024-1031. PubMed ID: 27685443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An analysis of 68 invasive lobular breast cancer cases in clinicopathological characteristics and the prognostic determinants].
    Liu Q; Xiang HY; Ye JM; Xu L; Zhang H; Zhang S; Duan XN; Liu YH
    Zhonghua Wai Ke Za Zhi; 2018 Feb; 56(2):119-123. PubMed ID: 29397625
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer.
    Abdelrahman AE; Rashed HE; Abdelgawad M; Abdelhamid MI
    Ann Diagn Pathol; 2017 Jun; 28():43-53. PubMed ID: 28648939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of girdin in human colorectal cancer and its association with tumor progression.
    Jun BY; Kim SW; Jung CK; Cho YK; Lee IS; Choi MG; Choi KY; Oh ST
    Dis Colon Rectum; 2013 Jan; 56(1):51-7. PubMed ID: 23222280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype.
    Braunstein LZ; Niemierko A; Shenouda MN; Truong L; Sadek BT; Abi Raad R; Wong JS; Punglia RS; Taghian AG; Bellon JR
    Breast J; 2015; 21(2):161-7. PubMed ID: 25559656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
    Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
    Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of tumor necrosis factor receptor-assicated factor 4 correlates with expression of Girdin and promotes nuclear translocation of Girdin in breast cancer.
    Wang A; Wang J; Sun L; Jin J; Ren H; Yang F; Diao K; Wei M; Mi X
    Mol Med Rep; 2015 May; 11(5):3635-41. PubMed ID: 25591657
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of ROR1 has prognostic significance in triple negative breast cancer.
    Chien HP; Ueng SH; Chen SC; Chang YS; Lin YC; Lo YF; Chang HK; Chuang WY; Huang YT; Cheung YC; Shen SC; Hsueh C
    Virchows Arch; 2016 May; 468(5):589-95. PubMed ID: 26874851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
    Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
    Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.